Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Boston Med Ctr
mi
from
Boston, MA
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
St. Louis University Cancer Center
mi
from
Saint Louis, MO
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
St. Louis University Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Georgetown University
mi
from
Washington,
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated:  4/30/2018
Detroit Clinical Research Center
mi
from
Novi, MI
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated: 4/30/2018
Detroit Clinical Research Center
mi
from
Novi, MI
Click here to add this to my saved trials
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated:  4/30/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated: 4/30/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated:  4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated: 4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated:  4/30/2018
Royal Adelaide Hospital
mi
from
Adelaide,
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Status: Enrolling
Updated: 4/30/2018
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/30/2018
Northwestern University
mi
from
Chicago, IL
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/30/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
Status: Enrolling
Updated:  5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
Status: Enrolling
Updated: 5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials